Skip to main content
OpenTrials

Clinical trial condition

Primary Immunodeficiency Diseases

Explore clinical trials studying Primary Immunodeficiency Diseases. Study availability and eligibility vary by location and protocol.

254 public trials 31 recruiting studies
Refine in advanced search Browse all conditions

Primary Immunodeficiency Diseases trial results

Completed

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

NCT00457015

Conditions
Angioedema, Angioedemas, Hereditary, Cardiovascular Diseases, +14 more
Locations
  • Aaron J. Davis Scottsdale, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Little Rock Allergy & Asthma Clinic Little Rock, Arkansas, United States
  • Alta Bates Comprehensive Cancer Center Berkeley, California, United States
View all 45 locations
View Trial Details
Completed

Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema

NCT02052141

Conditions
Angioedema, Angioedemas, Hereditary, Cardiovascular Diseases, +14 more
Locations
  • Asthma and Allergy Associates, P.C Colorado Springs, Colorado, United States
  • Nevada Access to Research and Education Society Las Vegas, Nevada, United States
  • Oregon Allergy Associates Eugene, Oregon, United States
  • Klinikum der J.W. Goethe Universitat Frankfurt, Germany
View Trial Details
Completed

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

NCT01095510

Conditions
Angioedema, Angioedemas, Hereditary, Cardiovascular Diseases, +14 more
Locations
  • Asthma & Allergy Associates, P.C. Colorado Springs, Colorado, United States
  • University of South Florida Asthma, Allergy and Immunology Clinical Research Unit Tampa, Florida, United States
  • Institute for Asthma and Allergy, PC Chevy Chase, Maryland, United States
  • Allergy & Asthma Research Group Eugene, Oregon, United States
View Trial Details
Completed

Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

NCT01756157

Conditions
Angioedema, Angioedemas, Hereditary, Cardiovascular Diseases, +14 more
Locations
  • ViroPharma Investigational Site Birmingham, Alabama, United States
  • ViroPharma Investigational Site Scottsdale, Arizona, United States
  • ViroPharma Investigational Site Bentonville, Arkansas, United States
  • ViroPharma Investigational Site Walnut Creek, California, United States
View all 23 locations
View Trial Details
Completed

Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects

NCT00432510

Conditions
Angioedema, Angioedemas, Hereditary, Cardiovascular Diseases, +14 more
Locations
  • University of California, San Diego San Diego, California, United States
  • Allergy and Asthma Clinical Research, Inc. Walnut Creek, California, United States
  • Family Allergy and Asthma Center Atlanta, Georgia, United States
  • Institute for Asthma and Allergy Wheaton, Maryland, United States
View Trial Details
Completed

Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)

NCT02865720

Conditions
Angioedema, Angioedemas, Hereditary, Cardiovascular Diseases, +14 more
Locations
  • Toyohashi Municipal Hospital Toyohashi, Aiti, Japan
  • Asahi General Hospital Asahi, Chiba, Japan
  • Gunma University Hospital Maebashi, Gunma, Japan
  • Kobe University Hospital Kobe, Hyōgo, Japan
View Trial Details
Completed

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

NCT02586805

Conditions
Angioedema, Angioedemas, Hereditary, Cardiovascular Diseases, +14 more
Locations
  • Clinical Research Center of Alabama, LLC Birmingham, Alabama, United States
  • Medical Research of Arizona Scottsdale, Arizona, United States
  • UC San Diego School of Medicine San Diego, California, United States
  • AIRE Medical of Los Angeles Santa Monica, California, United States
View all 41 locations
View Trial Details

Related conditions